Rheumatology Network's Top 5: February 11, 2022

Guselkumab Ranks Highest for Skin Clearance, Positive Joint Efficacy in PsA

Rheumatology Network interviewed Terence Rooney, MD, to discuss the findings of a Network Meta-Analysis that examined the efficacy of guselkumab (TREMFYA) for skin clearance and joint improvements in patients with psoriatic arthritis.

Upadacitinib Monotherapy Hinders Joint Damage in RA

Upadacitinib monotherapy was effective in inhibiting structural joint damage progression in patients with rheumatoid arthritis who were MTX-naïve or had an inadequate response to MTX.

High Rates of Depression and Food Insecurity Seen in Patients With RA

“Food insecurity may increase an individual’s dependence on inexpensive energy-dense foods that lead to the development of chronic diseases that may affect mental health," investigators stated.

Q&A: Obinutuzumab for the Treatment of Proliferative Lupus Nephritis

In this Q&A, corresponding author Richard A Furie, MD, discussed the findings of his study comparing obinutuzumab with placebo for the treatment of proliferative lupus nephritis in combination with standard therapies.
PsA Does Not Increase Risk of Venous Thromboembolic Events

PsA Does Not Increase Risk of Venous Thromboembolic Events

Given the recent concerns regarding venous thromboembolic events in patients with rheumatic disease and pre-existing cardiovascular risk factors being treated with tofacitinib, investigators addressed the occurrence of VTE in patients with PsA.